Calendario›REGN›Cemiplimab

Cemiplimab

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Ensayo de REGENERON PHARMACEUTICALS, INC. en High-Grade Glioma (HGG) · Posterior Fossa-A Ependymoma (del registro, en inglés).

Fase

Fase 1/2

Estado

Aún sin reclutar

Participantes

120

previstos

Fin del objetivo primario

ago 2032

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en ago 2026.

Qué mide

Occurrence of Treatment Emergent Adverse Events (TEAEs) (del registro, en inglés) (hasta 26 meses)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs"). The study is focused on children and young adults with recurrent or progressive High-Grade Glioma (HGG) or ependymoma. "Recurrent" means that the cancer came back after treatment. "Progressive" means that the tumor has grown or spread. The aim of the study is to see how safe, tolerable, and effective cemiplimab and the combination of fianlimab and cemiplimab are. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug(s) * Do the study drug(s) help study participants live longer without their tumors growing or spreading * How much of the study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug\[s\] less effective or lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07567469), actualizada en abr 2026.